ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 936,91
0,28%
Dow Jones
38 225,66
0,85%
DAX
17 936,42
0,17%
Brent Oil
83,76
0,16%
Bitcoin
59 208,66
0,15%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Alpine Immune Sciences Inc (ALPN)

  7. Alpine Immune Sciences Inc (ALPN) Actualités

ALPN Alpine Immune Sciences Inc

64,60
0,00 (0,00%)
03 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Alpine Immune Sciences Inc ALPN NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,00 0,00% 64,60 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
64,60
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
11/4/202422:27PRNUSKuehn Law Encourages ALPN, JBT, ELYM, and HRT Investors to..
11/4/202413:24IHMARKETNEWSCostco Increases Dividend by 14%, Meta Introduces ‘Artemis’..
10/4/202422:15BWAlpine Immune Sciences Shares Updated Clinical Data from..
10/4/202422:01BWVertex Enters Into Agreement to Acquire Alpine Immune..
01/4/202415:00BWAlpine Immune Sciences to Present Updated Clinical Data for..
21/3/202412:45BWAlpine Immune Sciences Presents New Translational Data on..
20/3/202421:30BWAlpine Immune Sciences to Participate in Upcoming H.C...
18/3/202421:05BWAlpine Immune Sciences Provides Corporate Update and Full..
07/3/202422:30BWAlpine Immune Sciences to Report Fourth Quarter and Full..
26/2/202422:30BWAlpine Immune Sciences to Participate in Two Upcoming..
14/2/202422:43EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202415:22EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
07/2/202422:12EDGAR2Form 8-K - Current report
01/2/202422:30BWAlpine Immune Sciences to Participate in Two Upcoming..
23/1/202400:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/1/202400:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/1/202400:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202422:45EDGAR2Form 8-K - Current report
05/1/202401:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202401:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/12/202322:23EDGAR2Form 8-K - Current report
21/12/202322:15BWAlpine Immune Sciences Announces Amendment of Acazicolcept..
18/12/202322:30BWAlpine Immune Sciences to Present at the 42nd Annual J.P...
22/11/202316:25EDGAR2Form SC 13D/A - General statement of acquisition of..
20/11/202322:30BWAlpine Immune Sciences to Participate in the Evercore ISI..
15/11/202315:00BWAlpine Immune Sciences Presents New Translational Data on..
14/11/202322:15BWAlpine Immune Sciences Reports Third Quarter 2023 Financial..
13/11/202315:00BWAlpine Immune Sciences Presents New Translational Data on..
07/11/202303:41BWAlpine Immune Sciences Announces Pricing of $150 Million..
07/11/202303:37EDGAR2Form FWP - Filing under Securities Act Rules 163/433 of free..
06/11/202312:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
06/11/202312:02EDGAR2Form 8-K - Current report
06/11/202312:00BWAlpine Immune Sciences Announces Proposed Public Offering
03/11/202314:00BWAlpine Immune Sciences Presents New Preclinical Data on..
02/11/202314:12EDGAR2Form 8-K - Current report
02/11/202314:00BWAlpine Immune Sciences Presents Initial Clinical Data on..
30/10/202314:00BWAlpine Immune Sciences to Present New Translational Data on..
13/10/202315:05BWAlpine Immune Sciences to Present Initial Clinical Data on..
04/10/202323:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/10/202323:11EDGAR2Form 3 - Initial statement of beneficial ownership of..
04/10/202314:00BWAlpine Immune Sciences Announces Appointment of Wolfgang..
12/9/202314:30BWAlpine Immune Sciences Presents First Preclinical Data for..
05/9/202322:30BWAlpine Immune Sciences to Participate in Two Upcoming..
05/9/202314:30BWAlpine Immune Sciences to Present First Preclinical Data for..
30/8/202322:30BWAlpine Immune Sciences Announces Initiation of Dosing in 240..
22/8/202322:30BWAlpine Immune Sciences Announces Appointment of M. Christina..
17/8/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
14/8/202322:26EDGAR2Form POS AM - Post-Effective amendments for registration..
14/8/202322:22EDGAR2Form 8-K - Current report
14/8/202322:18EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Dernières Valeurs Consultées

NASDAQ
ALPN
Alpine Immune Sciences
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés